Ritu Baral

Stock Analyst at TD Cowen

(0.98)
# 3,745
Out of 4,911 analysts
36
Total ratings
40%
Success rate
-12.53%
Average return

Stocks Rated by Ritu Baral

Palvella Therapeutics
Feb 5, 2025
Initiates: Buy
Price Target: $44
Current: $38.67
Upside: +13.78%
Sage Therapeutics
Nov 21, 2024
Maintains: Hold
Price Target: $10$9
Current: $8.80
Upside: +2.27%
Spero Therapeutics
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.33
Upside: -
AN2 Therapeutics
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.10
Upside: -
Avidity Biosciences
Oct 21, 2024
Maintains: Buy
Price Target: $56$78
Current: $36.27
Upside: +115.05%
Alnylam Pharmaceuticals
Oct 21, 2024
Maintains: Buy
Price Target: $282$371
Current: $328.81
Upside: +12.83%
Insmed
Aug 9, 2024
Maintains: Buy
Price Target: $75$98
Current: $103.95
Upside: -5.72%
Madrigal Pharmaceuticals
Mar 15, 2024
Maintains: Outperform
Price Target: $349$390
Current: $298.40
Upside: +30.70%
Sagimet Biosciences
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $10.24
Upside: -
Sarepta Therapeutics
Mar 22, 2023
Maintains: Outperform
Price Target: $125$175
Current: $11.93
Upside: +1,366.89%
Maintains: Outperform
Price Target: $32$21
Current: $23.25
Upside: -9.68%
Initiates: Outperform
Price Target: n/a
Current: $0.50
Upside: -
Initiates: Outperform
Price Target: n/a
Current: $14.50
Upside: -
Initiates: Outperform
Price Target: n/a
Current: $3.57
Upside: -
Initiates: Outperform
Price Target: n/a
Current: $21.81
Upside: -
Initiates: Outperform
Price Target: n/a
Current: $6.05
Upside: -
Initiates: Outperform
Price Target: n/a
Current: $1.57
Upside: -
Downgrades: Market Perform
Price Target: n/a
Current: $0.53
Upside: -
Downgrades: Market Perform
Price Target: n/a
Current: $735.01
Upside: -